Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
about
New Strategies for the Treatment of Solid Tumors with CAR-T CellsThe epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredInternalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.L-Tyrosine Confers Residualizing Properties to a d-Amino Acid-Rich Residualizing Peptide for Radioiodination of Internalizing Antibodies.Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant IIITherapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsTargeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression.Targeted therapy in head and neck cancer.Imaging EGFR and HER2 by PET and SPECT: a review.Recent progress in protein-protein interaction study for EGFR-targeted therapeutics.Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.A phase 1 study of ABT-806 in subjects with advanced solid tumors.
P2860
Q26748500-5FB910CF-4EA1-4E3F-97B4-14B1E7160148Q27015045-AFEC4BF9-5EEA-42DD-9B49-2279062428E0Q30480832-A73DEE85-6C95-4D94-B3CA-45BAED69DA57Q33721106-ABE2E642-DA66-4C23-8CE7-1E007B4E25DCQ33795428-DA52F013-3CCF-4CDF-8464-E655EC768119Q34568677-EF2BD713-E045-4D43-82CE-C64DD7053691Q35589285-7DC980A9-55B5-4745-9934-B221F7B59E13Q35652789-8E63ECD1-9486-455F-A238-7A9079041565Q36613969-286D04C8-8446-491C-82FB-36A6AD0A41B8Q36843748-76C53F88-6101-42C6-82CE-B47385EBA0DAQ37988981-170F4ACA-FE40-437B-83B3-D1A9D077AAC2Q38137829-F0859969-184E-41DF-BBD6-2EA3DE0EBC5DQ38899428-187BE478-910D-49D6-9EAA-72A394C4D9A9Q41022992-B032B512-EEF1-4386-ADF9-AEB252A6EB2EQ50561813-8F631D81-2EF6-4DDC-84B9-C77B637A6112
P2860
Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Engineering and characterisati ...... g de2-7 EGFR or amplified EGFR
@ast
Engineering and characterisati ...... g de2-7 EGFR or amplified EGFR
@en
type
label
Engineering and characterisati ...... g de2-7 EGFR or amplified EGFR
@ast
Engineering and characterisati ...... g de2-7 EGFR or amplified EGFR
@en
prefLabel
Engineering and characterisati ...... g de2-7 EGFR or amplified EGFR
@ast
Engineering and characterisati ...... g de2-7 EGFR or amplified EGFR
@en
P2093
P2860
P356
P1476
Engineering and characterisati ...... g de2-7 EGFR or amplified EGFR
@en
P2093
A Kypridis
A W Burgess
C Panousis
G Cartwright
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602470
P407
P50
P577
2005-03-01T00:00:00Z
P5875
P6179
1010759127